Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of [18F]ABBV-964i and [18F]ABBV-965i PET Radioligands in PSP and Healthy Volunteers
NCT07348276Phase 1Completed
- Sponsor
- Invicro
- Start
- Nov 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]ABBV-964i and [18F]ABBV-965i in progressive supranuclear palsy (PSP) (3 arms), sponsored by Invicro. Primary endpoints: Incidence of Adverse Events up to 13 weeks and Radiation dosimetry up to 13 weeks. Started Nov 2025; status: completed.
02
Drugs
[18F]ABBV-964i[18F]ABBV-965i
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT07348276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348276.